Performance of a smartphone-based stool test for use in colorectal cancer screening: population-based study
Background & Aims - Noninvasive colorectal cancer (CRC) screening bears high potential for increasing participation if implemented in a straightforward way. We have evaluated the feasibility and diagnostic performance of a smartphone-based fecal immunochemical test (FIT) for CRC screening and co...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
19 December 2025
|
| In: |
Clinical gastroenterology and hepatology
Year: 2026, Jahrgang: 24, Heft: 1, Pages: 241-249.e3 |
| ISSN: | 1542-7714 |
| DOI: | 10.1016/j.cgh.2025.04.027 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.cgh.2025.04.027 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1542356525004239 
|
| Verfasserangaben: | Michael Hoffmeister, Teresa Seum, Leopold Ludwig and Hermann Brenner |
| Zusammenfassung: | Background & Aims - Noninvasive colorectal cancer (CRC) screening bears high potential for increasing participation if implemented in a straightforward way. We have evaluated the feasibility and diagnostic performance of a smartphone-based fecal immunochemical test (FIT) for CRC screening and compared its performance with a laboratory-based FIT. - Methods - Individuals scheduled for a screening colonoscopy in gastroenterology practices in Southern Germany enrolled into the BLITZ study between 2021 and 2023 were offered a smartphone-based FIT and a laboratory FIT. The smartphone-based FIT consists of a rapid test and a smartphone app. The app quantitatively evaluates the result of the rapid test using the smartphone camera. The feasibility of the smartphone-based FIT was evaluated in a self-administered questionnaire. The comparative performance of the 2 FITs was evaluated by sensitivity, specificity, and receiver-operator curve (ROC) measures. - Results - Of 654 study participants who were offered both a smartphone-based FIT in addition to the laboratory FIT, 361 (55%) made use of the smartphone-based FIT, 274 (76%) of those had a valid smartphone-based FIT, and 643 (98%) used the laboratory FIT. Overall, 89% considered the smartphone-based FIT as a useful alternative offer to the laboratory FIT. The reasons why the smartphone-based FIT was not used were mostly technical (app- or smartphone-related, 47%) or reflecting more general concerns or attitudes towards such a test (44%). The smartphone-based FIT showed a sensitivity for advanced neoplasms (28%; 95% confidence interval [CI], 13%-47%) similar to the laboratory FIT (34%; 95% CI, 18%-54%) at an identical specificity (92%; 95% CI, 87%-95%). - Conclusions - The smartphone-based FIT could serve as an alternative in addition to currently offered laboratory FITs. |
|---|---|
| Beschreibung: | Gesehen am 18.03.2026 |
| Beschreibung: | Online Resource |
| ISSN: | 1542-7714 |
| DOI: | 10.1016/j.cgh.2025.04.027 |